TTPH - Tetraphase Pharmaceuticals - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

Tetraphase Pharmaceuticals's activity chart (see below) currently has 49 price targets and 44 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 50.9% with an average time for these price targets to be met of 84.23 days.

Most recent stock forecast was given by KEVIN KEDRA from GABELLI on 07-May-2020. First documented stock forecast 05-Mar-2014.

Best performing analysts who are covering TTPH - Tetraphase Pharmaceuticals:

Jim Birchenough Brian Skorney Alan Carr Daniel Brims Heather Behanna

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

6 years 5 months 15 days ago
(07-May-2020)

1/2 (50%)

$36.05 (72.09%)

304

Hold Since 03-Sep-2019

$140

7 years 1 months 19 days ago
(03-Sep-2019)

0/3 (0%)

$69.6 (98.86%)

Buy Since 19-Nov-2015

$4

$1.8 (81.82%)

7 years 5 months 13 days ago
(09-May-2019)

1/2 (50%)

$-16 (-80.00%)

151

Buy Since 11-Sep-2017

$4

$1.8 (81.82%)

7 years 7 months 7 days ago
(15-Mar-2019)

1/3 (33.33%)

$-24.2 (-85.82%)

206

$140

$137.8 (6263.64%)

$120

8 years 1 months 24 days ago
(28-Aug-2018)

0/3 (0%)

$69.6 (98.86%)

Show more analysts

Please expand the browser size to see the chart

What is TTPH (Tetraphase Pharmaceuticals) average time for price targets to be met?

On average it took 84 days for the stock forecasts to be reached, with an average price target met ratio of 50.9%.

Which analyst most recently updated their price target on TTPH (Tetraphase Pharmaceuticals)?

Kevin Kedra

Which analyst has the most public recommendations on TTPH (Tetraphase Pharmaceuticals)?

Kevin Kedra has 2 price targets and 2 ratings on TTPH

Which analyst is the currently most bullish on TTPH (Tetraphase Pharmaceuticals)?

Alan Carr with the highest potential upside of $1117.8

Which analyst is the currently most reserved on TTPH (Tetraphase Pharmaceuticals)?

Kevin Kedra with the lowest potential downside of -$0
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?